Application of Dalacin gel for acne, blackheads and comedones

Dalatsin is one of the most effective remedies for acne on the face, which, if used correctly, can speed up skin cleansing and prevent new breakouts. The drug, due to the antibiotic Clindamycin included in the composition, copes well with inflammatory processes that have arisen in the epidermis.

Pharmacological properties of the drug Dalacin c

Pharmacodynamics. The active substance of the drug is clindamycin, a semisynthetic antibiotic that is synthesized from lincomycin by replacing the 7-(R)-hydroxyl group with 7-(S)-chloro. Depending on the sensitivity of the microorganism and the concentration, clindamycin can act bactericidal or bacteriostatic. In vitro active against microorganisms. Aerobic gram-positive cocci, including Staphylococcus aureus; Staphylococcus epidermidis (including strains that produce and do not produce penicillinase). During in vitro , rapid development of drug resistance was noted in some strains resistant to erythromycin; streptococci (except fecal streptococcus), pneumococci; anaerobic gram-negative bacteria, including Bacteroides spp. (including the B. fragilis, B. melaninogenicus ), Fusobacterium spp. ; anaerobic gram-positive non-spore-forming bacteria, including Propionibacterium, Eubacterium, Actinomyces spp. ; anaerobic and microaerophilic gram-positive cocci, including Peptococcus spp., Peptostreptococcus spp. , Microaerophylis streptococci ; Clostridium spp. Clostridia are more resistant to clindamycin than many other anaerobes. Most clostridia, especially Clostridium perfringens, are sensitive to clindamycin, but some species (eg C. sporogenes and C. tertium ) are often resistant to clindamycin. In this regard, it is necessary to test for sensitivity to the antibiotic. In vitro studies have shown that strains of microorganisms such as Bacteroides melaninogenicus, B. disiens, B. bivius, Peptostreptococcus spp., Gardnerella vaginalis, Mobiluncus mulieris, M. curtisii, Mycoplasma hominis . Pharmacokinetics. After oral administration of a dose of 150 mg of clindamycin hydrochloride, rapid and almost complete (90%) absorption of clindamycin occurs. The maximum level of the drug in the blood serum (2.5 μg/ml) is achieved after 45 minutes, after 3 hours the drug concentration is 1.51 μg/ml and after 6 hours - 0.7 μg/ml. After oral administration, almost complete (90%) absorption of clindamycin occurs; simultaneous food intake does not affect the concentration of clindamycin in the blood serum. A study of serum concentrations of the drug with prolonged use of clindamycin hydrochloride (for 14 days) did not reveal the accumulation of the drug or changes in its metabolism. The half-life of clindamycin is slightly increased in patients with significantly impaired renal function. Hemodialysis and peritoneal dialysis are not effective for removing clindamycin from the blood. Clindamycin serum concentrations increase linearly with increasing doses. The serum concentration of the drug already 6 hours after administration at the usual dose exceeds the minimum inhibitory concentration relative to most of the above-mentioned microorganisms. Clindamycin is widely distributed in tissues and body fluids (including bone tissue). The average biological half-life is 2.4 hours. About 10% of the active drug is excreted in the urine, 3.6% in feces, and the rest of the drug in the form of inactive metabolites. Clindamycin 2.0 g for 14 days was well tolerated by healthy volunteers, although an increase in gastrointestinal side effects was noted with increasing doses. In the CSF, even against the background of an inflammatory process, significant concentrations of clindamycin are not achieved. When administered orally, clindamycin hydrochloride was observed to increase the half-life to an average of 4 hours (range 3.4–5.1 hours) in elderly patients compared with 3.2 hours (range 2.1–5.1 hours) in younger patients. 4.2 hours). However, the degree of absorption in different age groups did not differ significantly, so there is no need to adjust the dose of the drug in elderly patients with normal (corresponding to age-related changes) liver and kidney function.

Indications for use of the drug Dalacin c

Dalatsin C and Dalatsin S Phosphate is an effective remedy in the treatment of infections caused by pathogens sensitive to it:

• infections of the ENT organs, including pharyngitis, sinusitis, otitis media, scarlet fever;
• lower respiratory tract infections, including bronchitis, pneumonia, lung abscess, pleural empyema;
• infections of the skin and soft tissues, including acne, furunculosis, cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of the skin and soft tissues caused by pathogens sensitive to this drug, such as erysipelas and paronychia/felon;
• infections of bones and joints, including osteomyelitis and purulent arthritis;
• gynecological infections, including endometritis, phlegmon, colpitis, tubo-ovarian abscesses, salpingitis and pelvic inflammatory diseases, if the drug is prescribed in combination with an appropriate antibiotic active against gram-negative pathogens. For cervical infections caused by Chlamydia trachomatis , clindamycin monotherapy is effective in eradicating this organism;
• intra-abdominal infections, including peritonitis and abscesses of the abdominal organs (in combination with antibiotics acting on gram-negative aerobes);
• septicemia and endocarditis. The effectiveness of clindamycin has been proven in certain cases of endocarditis: the drug has a bactericidal effect on the infectious agent in vitro when using such concentrations of the drug that are achieved in human blood serum;
• oral infections, including periodontal abscess and periodontitis;
• toxoplasmic encephalitis in patients with AIDS (the effectiveness of clindamycin in combination with pyrimethamine has been proven in patients intolerant to standard therapy);
• Pneumocystis pneumonia in patients with AIDS (in patients who cannot tolerate or are resistant to standard therapy, clindamycin can be used in combination with primaquine);
• malaria, including cases caused by multidrug-resistant Plasmodium falciparum (as monotherapy or in combination with quinine or chloroquine);
• prevention of endocarditis in patients with hypersensitivity to penicillins;
• prevention of wound infection during surgical interventions in the head and neck area;
• prevention of peritonitis and intra-abdominal abscesses after perforation and post-traumatic contamination when used simultaneously with aminoglycoside antibiotics (gentamicin or tobramycin).

Reviews

We invite you to read reviews from ordinary people about the use of Dalatsin for acne, and if you still have any questions, you can always ask them to a cosmetologist or pharmacist on our cosmetic forum.

I suffered from an inflammatory process of the skin - acne of 3 degrees of severity. A combination of dalacin and basiron helped. I applied Dalacin to cleansed skin in the morning and evening, and baziron only before bed. After three months, the skin was clear, only spots remained from acne, which I took a long time to remove with peelings.

Diana, 22 years old, Klin

I often encounter extremely strange inflammations on my back and neck. The dermatologist prescribed Dalatsin gel. I applied it to inflammations 2-3 times a day, not only to ulcers, but also to newly appeared inflammations. Most inflammations do not fill with pus, but simply resolve within one day.

Sasha, 26 years old, Tula

Every spring and autumn I experience severe flare-ups and extensive rashes on my temples and chin. In the fight against this, a mask with white clay and dalacin helps me a lot. I do it three times a week, on Mondays, Wednesdays and Saturdays. And in the evening, before going to bed, I cauterize the pimples with alcohol tincture of calendula and a little later apply dalacin. Pimples mature faster and break out, and new rashes do not appear.

Lena, 28 years old, Istra

Use of the drug Dalacin c

The dose and method of administration of the drug depend on the severity of the disease, the patient’s condition and the sensitivity of the infectious agent to the antibiotic. The course of treatment lasts on average 7–10 days. Adults Dose of Dalacin C in capsule form for oral use: 600–1800 mg per day, divided into 2, 3 or 4 equal doses. In order to prevent possible irritation of the esophagus, Dalacin C capsules should be taken with a full glass of water. Capsules should not be opened. Children over 6 years of age The dose of Dalacin C is 8-25 mg/kg per day in 3-4 doses. To avoid irritation of the esophageal mucosa, capsules should be taken with a full glass of water. Elderly patients No dosage adjustment is required in elderly patients with normal liver and kidney function. Patients with renal failure Patients with renal failure do not require dose adjustment. Patients with liver failure Patients with liver failure do not require dose adjustment.

Side effects

If the drug is used incorrectly, the risk of an allergic reaction or irritation increases sharply.

The most common reasons are:

• High skin sensitivity to active substances;
• Applying the drug in a thick layer;
• Presence of contraindications for use.
• Immediate reactions may be accompanied by:
• Skin rashes;
• Peeling;
• Burning;
• Dryness;
• Itching;
• Local swelling;
• Redness;
• Urticaria;
• Dermatitis.

Since the main active ingredient of the drug is an antibiotic, it is not recommended to use Dalatsin on an ongoing basis, but it is also necessary that the duration of the course of treatment be sufficient so that the bacteria do not have time to develop addiction. Typically, at least 2 weeks per affected area.

Do not use simultaneously with sulfonamide drugs, pyrazolone derivatives, or cytostatics. If the patient has been taking antibiotics from the lincosamide group, for example Lincomycin, for a year, then the effectiveness of Dalatsin will be weaker, and the likelihood of developing side effects will also increase.

Instructions for the gel

Special instructions for the use of Dalacina C

for selected indications Treatment of infections caused by β-hemolytic streptococcus. For infections caused by β-hemolytic streptococcus, treatment must be continued for at least 10 days. Treatment of acute streptococcal tonsillitis/pharyngitis. The dose of Dalacin C in capsules for oral use is 300 mg 2 times a day for 10 days. Treatment of inflammatory diseases of the pelvic organs. After parenteral administration of the drug for 6 days, clindamycin hydrochloride should be continued orally at a dose of 450–600 mg every 6 hours until completion of the 10–14 day therapy cycle. Cervical infections caused by Chlamydia trachomatis 450–600 mg Dalacin C orally 4 times a day for 10–14 days. Toxoplasmosis encephalitis in patients with AIDS. Dalacin C orally at a dose of 600–1200 mg every 6 hours for 2 weeks, then 300–600 mg orally every 6 hours. The course of therapy is usually 8–10 weeks. The dose of pyrimethamine is 25–75 mg orally daily for 8–10 weeks. When using pyrimethamine in higher doses, folinic acid should be prescribed at a dose of 10–20 mg/day. Pneumocystis pneumonia in patients with AIDS. Dalacin C 300–450 mg orally every 6 hours for 21 days and primaquine 15–30 mg orally once a day for 21 days. Treatment of malaria. Adults are prescribed at a dose of 10–20 mg/kg per day, children - 10 mg/kg per day in equal doses 2 times a day for 7 days as monotherapy or in combination with quinine (12 mg/kg 2 times a day) or chloroquine (15–25 mg once daily) for 3–5 days. Prevention of endocarditis in patients with hypersensitivity to penicillin. Adults are prescribed 600 mg 1 hour before surgery or a therapeutic and diagnostic procedure (for example, tonsillectomy, adenoidectomy, bronchoscopy with a rigid bronchoscope, dilation of esophageal stricture, retrograde cholangiopancreatography, cystoscopy, etc.); children - 20 mg/kg 1 hour before surgery or diagnostic and treatment procedures.

Side effects of the drug Dalacin c

blood and lymphatic system: transient neutropenia/leukopenia, eosinophilia, agranulocytosis, thrombocytopenia (no clear cause-and-effect relationship with the use of Dalacin C has been established); immune system: anaphylactoid reactions; nervous system: dysgeusia; Gastrointestinal tract: abdominal pain, nausea, vomiting, diarrhea, esophagitis, esophageal ulcer; hepatobiliary disorders: jaundice, changes in liver function tests (including hyperbilirubinemia); skin, subcutaneous tissue and mucous membranes: maculopapular rash, urticaria, mild or moderate generalized rash, erythema multiforme, Stevens-Johnson syndrome, itching, vaginitis, exfoliative and vesiculobullous dermatitis, toxic epidermal necrolysis.

Special instructions for the use of the drug Dalacin c

Treatment with clindamycin, like other antibiotics, may be complicated by the development of pseudomembranous colitis. Therefore, it is important to promptly diagnose this pathology in patients with diarrhea while using antibacterial agents and discontinue the drug. Antibacterial drugs inhibit the functioning of the normal flora of the large intestine, which can cause rapid proliferation of clostridia. The results of the studies indicate that toxins produced by clostridia, especially Clostridium difficile , are the most important and direct cause of the development of colitis. If pseudomembranous colitis develops, appropriate treatment should be prescribed. In mild cases of pseudomembranous colitis, discontinuation of clindamycin may be sufficient. With the development of a moderate and severe form, it is necessary to carry out appropriate therapy, which includes the use of fluids, solutions of electrolytes and protein preparations and the use of drugs that are effective against the pathogen - Clostridium difficile . Clindamycin should not be used to treat meningitis because the drug does not penetrate the CSF well. With long-term treatment with antibacterial drugs, it is necessary to monitor liver and kidney function. As a result of clindamycin therapy, microflora that are insensitive to this drug, especially yeast, may be activated. Cases of diarrhea associated with Clostridium difficile have been reported with the use of almost all antibacterial agents, including clindamycin. The severity of diarrhea can range from moderate to severe fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to an increase in Clostridium difficile . C. difficile produces exotoxins A and B, which cause Clostridium difficile -associated diarrhea. Toxin-overproducing strains of C. difficile cause increased morbidity and mortality because these infections may be refractory to antibiotic therapy; Sometimes a colectomy may be necessary. In patients who have developed diarrhea syndrome during the use of antibiotics, it is necessary to exclude the possibility of developing Clostridium difficile -associated diarrhea. Careful monitoring and maintenance of the patient's medical records is necessary from the moment of reporting the occurrence of Clostridium difficile -associated diarrhea until 2 months after the use of antibacterial agents. During pregnancy and breastfeeding. Clindamycin is able to cross the placenta. With long-term use, the level of clindamycin in amniotic fluid is about 30% of the drug concentration in the mother's blood. Dalatsin C can be prescribed during pregnancy only in case of urgent need. Clindamycin has been reported to pass into breast milk at concentrations of 0.7–3.8 mcg/ml. It is recommended to stop breastfeeding while using Dalatsin C. Impact on the ability to drive vehicles and work with potentially dangerous mechanisms. There is no data indicating the effect of Dalatsin C on the ability to drive vehicles and operate machinery.

Contraindications

Dalatsin has a relatively small number of contraindications, these include:

• Age up to 12 years;
• Hypersensitivity to clindamycin or lincomycin;
• High sensitivity to the components of the drug;
• Crohn's disease;
• Various colitis;
• Taking muscle relaxants.

I also did not recommend the use of Dalatsin during pregnancy, since it can enter the systemic circulation and potentially penetrate the placental barrier, as well as during lactation, since there is insufficient data on this topic in the studies conducted.

Drug interactions Dalacin c

Cross-resistance exists between clindamycin and lincomycin. also in vitro antagonism between clindamycin and erythromycin. The drug is also incompatible with ampicillin, barbiturates, aminophylline, calcium gluconate, magnesium sulfate. Due to the potential clinical significance of this interaction, these agents should not be coadministered. Concomitant use with antidiarrheal drugs increases the risk of pseudomembranous colitis. Clindamycin has the ability to block neuromuscular transmission and may enhance the effect of other neuromuscular blockers, so the drug should be used with extreme caution in patients prescribed muscle relaxants.

Analogs

If you want something inexpensive, but very effective, then we recommend turning your attention to the following drugs. Dalatsin has the following analogues, which are divided into several groups.

With antibiotic

These creams contain components of similar (or the same) action (one or more), but in different dosages, these include:

• Klindovit;
• Klenzit – C;
• Sintomycin;
• Levosin;
• Levomethyl;
• Levomekol;
• Tetracycline;
• Erythromycin;
• Dioxidine.

No antibiotic

These ointments and creams have different ingredients, dosages, indications and contraindications, but they have similar pharmaceutical effects.

Non-structural analogues include:

• Metrogyl gel (Rozamet cream);
• Liniment Vishnevsky;
• Ichthyol ointment;
• Stellanin;
• Baneocin.

Cheaper, more effective and accessible analogues are the following drugs: lincomycin and erythromycin.

• 
  Erythromycin

• 
  Levomekol

Before purchasing an analogue, it is strongly recommended to consult a dermatologist (the analogue may not be suitable for the patient to treat inflammation that he has developed).